AVANIR Pharmaceuticals (FRA:AV2B) Total Current Assets : €233.43 Mil (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. AVANIR Pharmaceuticals's total current assets for the quarter that ended in Sep. 2014 was €233.43 Mil.

AVANIR Pharmaceuticals Total Current Assets Historical Data

The historical data trend for AVANIR Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Total Current Assets Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Total Current Assets

Get a 7-Day Free Trial

31.05

61.35

62.79

53.74

233.43

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Total Current Assets	Get a 7-Day Free Trial															53.74	40.96	56.17	82.87	233.43

AVANIR Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

AVANIR Pharmaceuticals's Total Current Assets for the fiscal year that ended in Sep. 2014 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	210.971	+	17.717	+	0.62	+	4.126
	=	233.43

AVANIR Pharmaceuticals's Total Current Assets for the quarter that ended in Sep. 2014 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	210.971	+	17.717	+	0.62	+	4.126
	=	233.43

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

AVANIR Pharmaceuticals (FRA:AV2B) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

AVANIR Pharmaceuticals's Liquidation Value for the quarter that ended in Sep. 2014 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	210.971	-	26.069	+	0.75 * 17.717	+	0.5 * 0.62
=	198.50

AVANIR Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Total Current Assets

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines